Friends of Grover Powers. The late Daniel Darrow, a long-time and dis. tinguished member of your faculty, in 1946, on dedicating his first 76 sci. entific papers in a bound volume to Grover Powers, inscribed it as follows: "To Grover F. Powers, whose faith in people made this work possible." Faith in people is perhaps the best way to characterize Grover Powers' basic attitude in life and this faith colored all his work in pediatrics and medical education. In lauding Grover Powers, as a truly lasting and vital influence on so many, we can take joy in the model department he built here at Yale. He brought Milton Senn to Yale, and there came and continue to come since then, under Dr. Cook's leadership, a group of idealistic, dedicated, and able young men and women among whom are clearly tomorrow's great names.
He would call at the end of his daily ward rounds, Dr. Taffel or Dr. German, or Dr. Wilson, or Dr. Canfield, the entire brain trust sometimes, repeating "that six hats are better than one, especially if they are top hats." We never felt he was by-passing the residents when he did this, because all of us were so busy trying to solve the puzzle at hand with him that we didn't feel left out. Nor did his clinical problem solving limit itself to clinical consultations. I remember a little baby who was mentally retarded and had a high-pitched cry and a high fever which he thought could not be infectious. He called John Brobeck from pathology to come down and talk to us about hypothalamic fevers.
It is now commonplace to talk about the New Pediatrics. People who don't know Dr. Powers may not know that he was indeed a great innovator in pediatrics. Many practices which are now absolutely routine were started by him. He was "thoroughly modern."
Dr. Marian C. Putnam, I believe, was the first fulltime member of any pediatric department who was an analytic psychiatrist, and later Dr. Edith Jackson joined the department as a fulltime psychiatrist. Some of you may remember Miss Rice, a social worker who did weekly ward rounds at a time when that was considered radical. You may remember a classic paper by Powers entitled "Humanizing Hospital Experiences."' This modest paper contains in it all the things we now take so for granted in hospital practice: Liberalizing visiting hours, having stockings on children's feet when they are cold, giving parents easy access to the child, feeding the sick child what he likes, not what he should have, and trying to cause the least amount of pain, and many more. Rooming-in as a medical-school sponsored activity was encouraged by Dr. Powers and home visits with new babies became routine for all of us on the house staff and in the medical school. He felt that above all one should do no harm. He had a horror of iatrogenic disease. I might say a word about this because it will lead directly to the subject of my talk on routine smallpox vaccination which is, after all, a deliberate and universal iatrogenic disease. Once when we saw a child who was suffering from a serious complication of smallpox vaccination, I, who had just worked for three years in a smallpox area during my Army service pointed out fairly blithely that occasional serious complications were bound to occur with anything, and that this is simply a risk we have to take. I remember that is exactly what I said: "That is a risk we have to take." He looked very sad. He looked at me, he looked at the baby, finally he said: "Who has to take? Who asked him?" It was a comment that hasn't been forgotten.
It is my view that, in the United States, the relative risk of a newborn child contracting smallpox from an accidental importation is considerably smaller than the known risk of routine primary smallpox vaccination for all infants, as currently advocated.
Routine smallpox vaccination was highly justified when virulent smallpox was a real threat to the lives of young children in this country. There is no question that almost universal smallpox vaccination is responsible for the eradication of the disease from North America. The freedom from the virulent, major form of smallpox that this country has enjoyed since 1949 is widely but erroneously believed to be evidence of a high level of immunity among our population. Actually, the United States is no better protected than Sweden, Poland, Great Britain, or the rest of Western Europe, where in 1963, the importation of four cases resulted in 141 secondary cases with eleven deaths.' As a nation, we can be said to be well vaccinated but not well immunized. While it is true that fatalities from smallpox are less common in anyone who has ever been vaccinated, it is also true that within one year after primary vaccination the chance of an attack of smallpox is reduced to 1/1,000 of that in the unvaccinated, within three years to 1/200, within ten years to 1/8, within twenty years to 1/2, and after twenty years there is little protection from clinical infection. It is clear from the above that routine primary vaccination of all infants does not, even in our current situation, intend to protect against the disease, which might be encountered in a trip to an endemic area twenty years hence.! The principle reason for early vaccination is the feeling, on many people's part, that the risk of serious complications-particularly encephalitis-is significantly less in the young and is largely limited to primary rather than repeat vaccination.'
Credit for first employing an attenuated vaccine for smallpox goes to the late Dr. Thomas Rivers whose strain of vaccinia had been passed in chick embryo tissue cultures.' Dr. Rivers was pleased to note that this attenuated strain, free of bacteria and given intradermally, caused no skin necrosis or scars and a minimal amount of fever or systemic reactions. Unfortunately, he found that revaccination with the standard strain of vaccinia 12 months later resulted in a major vaccinoid reaction in the majority of these children.' He discarded this attempt because he feared that primary vaccination with the attenuated strain did not provide as much immunity against smallpox as the standard strain.' It is clear to us now, however, that primary vaccination in this country need not be highly effective for immediate protection against smallpox, because in the absence of exposure to smallpox it is not the primary nor, indeed, the second or third vaccination which is likely to be of significance in protection against smallpox if one considers that it is virtually impossible for an American child to be exposed to smallpox until he travels into a smallpox endemic region in Africa or Asia, probably after his 18th birthday. On the other hand, it is the primary vaccination which is of greatest concern from the point of serious complications. Most of the deaths of vaccination are encountered in primary vaccinations, as are most cases of postvaccinal encephalitis.8 Clearly, the initial sensitizing experience with vaccinia antigen need not result in as high a degree of immunity against smallpox as was formerly believed, provided only that it indeed caused lesser complications than the routine vaccine universally in use.
The strain used in these studies is derived from the "First Revived Strain" of Dr. Thomas Rivers which originated from the dermal vaccine virus of the New York Board of Health. A specimen from Lot 611 of this original strain, received by Dr. Rivers at the Rockefeller Institute of Medical Research in 1931, was subsequently propagated by him through four intratesticular passages in rabbits, and then serially in a medium of chick embryonic tissue in Tyrode's solution. Virus from the 34th passage in this series was then passed six times through rabbit testes and cultivated serially in chick embryonic tissue by Dr. R. F. Parker, of Western Reserve University.' Material in the 59th passage in this series was received by us in 1946 at the Walter Reed Army Institute of Research and further passed on chicken-egg chorioallantoic membranes for an additional nineteen passages. This strain is designated as CVI-78; its infectivity titer is 8.4 TCID 50/ml., and it is free of bacteria or known extraneous agents.
In 1948, we began to work with this strain of vaccinia virus. It was clear from the start that this further attenuated strain (CVI-78) caused less skin necrosis in rabbits and children regardless of the route of administration. The attenuated strain of vaccinia virus was at first used in those children who are now excluded from routine vaccination in infancy and who are at risk from accidental contamination with vaccinia from a vaccinated sibling or classmate. There are some 90,000 children each year with infantile eczema among the 5,000,000 infants born and they are potentially at risk from eczema vaccinatum. Many studies have shown that eczema vaccinatum is a much more serious disease in accidentally contaminated infants than an elective primary vaccination of eczema patients who only occasionally will generalize their virus infection. We, therefore, limited our first experience with the attenuated strain to the elective vaccination of children with eczema. Table 1 shows the dosage schedule used in the first 594 children who received CVI-78. It should be noted that 406 of the children received routine multiple pressure vaccination while the remainder received subcutaneous inoculation of varying dosages of vaccine diluted 1:100 or 1:1000. Table 2 shows the delivered virus dose for these different methods of inoculation which ranged from the variable inoculum of multiple pressure vaccination to a dose of 1,000 TCID50 for the 0.1 ml. of 1:1000 subcutaneous inoculation. Table 2 also shows the geometric mean of neutralizing titers one month after such vaccination for each dosage schedule. It should be noted that routine vaccination of normal children receiving standard vaccine results in a geometric mean titer of 48.5. Sero conversion occurred in all children receiving even the lowest inoculated dose of 1,000 TCID50, although the sponses than eczematous children ieceiving the attenuated strain. Table 3 compares the geometric mean of the neutralizing titer with the various routes and doses of inoculation to the maximal fever shown. It will be seen that there is no evidence that higher fevers result in higher antibody titers. Table 4 classifies local reactions in an arbitrary fashion from 0 to 4+ in the eczematous children receiving primary vaccination with the attenuated strain. It is of interest that subcutaneous inoculation does not result in a skin lesion of any kind. Thus, a 1 to 3 + reaction refers to the degree of erythema and subcutaneous local tenderness and swelling at the site of vaccination generally 10 days after inoculation. Multiple pressure vac-Attenuated smallpox vaccine I KEMPE cinations, on the other hand, are similar in appearance to those obtained with standard vaccine except for a reduction in erythema and swelling and only an occasional occurrence of axillary lymphadenopathy. The single 4+ reaction was a case of mild erythema multiforme, in an incidence similar to that expected with routine primary vaccination. Table 5 attempts to roughly classify systemic reactions. Any degree malaise was classified as 1 +, a single case of erythema multiforme was classified as 3 +. It will be seen that close to 90%o of children had no systemic reaction to this vaccine. It should be stressed that generalization of virus did not occur.
It is not known what the incidence of eczema vaccinatum is in the deliberate primary vaccination of children with eczema because it is a procedure specifically contraindicated in pediatric practice. On the other hand, each year, the American Red Cross consultants on the vacciniaimmune gammaglobulin distribution program, receive approximately 60 If present experience continues, it is likely that those who wish to continue routine primary vaccination will be able to use an attenuated strain for primary vaccination and follow this subsequently with the current vaccine when protection against smallpox becomes desirable. I believe such a vaccine will be available to physicians within a few years.
It would seem logical, inasmuch as the next two or three years are unlikely to make any difference whatever in terms of exposure to smallpox, that routine primary vaccination with the current virulent strain could be halted and that subsequently, if desired, the two-step immunization with attenuated live vaccinia could be instituted. Conversely, the primary vaccination with the modified attenuated strain of vaccinia could be done at such time as an indication exists and routine vaccination discontinued.
If routine primary vaccination were innocuous, and if it provided "herd immunity" by giving partial protection, and if it interfered with the spread of smallpox upon an importation, a case could be made for continuing with the current method and the current strain. On the other hand, we are not accomplishing what we are trying to do because, while young children are excellently protected against smallpox, they are not in circulation sufficiently to be an important population barrier to importation-on the other hand, young adults have a relatively high rate of susceptibility. For example, 85%o of our military recruits respond to routine smallpox revaccination with a major reaction as defined by the W.H.O. Expert Committee.'0
To truly provide an immune population, revaccination of the entire population every three to five years would be essential. While this is highly desirable for nurses, physicians, and other hospital personnel, as well as the Armed Forces, and yearly revaccination is advised for individuals engaged in foreign travel to smallpox-endemic regions, nobody has seriously suggested mass campaigns in the population at large.
The mortality and morbidity from routine infant smallpox vaccination in this country is now truly appalling when compared to the risk of smallpox. ' We believe that the death rate from routine vaccination is between 1 and 1.5 per million vaccinees, with a much higher death rate in primary than in repeat vaccination. The morbidity data for 1963 suggest that the total cost of hospitalization was in excess of $80,000 per year for treatment of patients with complications. The incidence of post-vaccinia encephaltis would appear to be at least 1/100,000 in primary vaccinees, and this would assume 60 cases in 1963. The last smallpox death in the United States following an importation occurred in 1948, but since that time there have probably been 200 to 300 deaths from smallpox vaccination. Assuming a mortality rate of 30% from variola major, the number of smallpox cases in the United States would have had to be between 600 and 900 during this period to equal the mortality from vaccination.! No other routine immunization procedure in this country has anything like the morbidity and mortality of routine smallpox vaccination. Admittedly, it is difficult to assess what constitutes a complication. By definition, a successful vaccination represents a deliberate iatrogenic infection, the expected morbidity of which includes fever as well as other systemic symptoms, and local inflammation and necrosis is an expected finding. No one has yet defined clearly what findings beyond the expected constitute major morbidity. But, by comparison, it is conservatively estimated that before the advent of measles immunization approximately 500 children died each year as a result of measles, and measles encephalitis occurs as often as 1 in 400 cases. If, in order to prevent these 500 deaths and the numerous other serious complications of wild measles, the Enders attenuated measles vaccine had promised solid protection and life-long immunity against measles, but also had caused a mortality of 1 to 1.5 per million vaccinees and had resulted in an incidence of encephalitis of 1 in 100,000, I do not believe this product would have been licensed in this country. In all prophylactic, diagnostic, and therapeutic efforts, the risk of the procedure is always considered in relation to the risk of the condition we try to prevent, diagnose, or cure. The majority of workers in the field of public health sincerely feel that the current morbidity and mortality from routine vaccination is "the price we have to pay" for keeping our country free of smallpox. Those responsible for the care of children, on the other hand, must now look to the welfare of each child and remember the dictum "First, do no harm." At the very least, parents should have a choice to decide this matter in collaboration with their physician and based on the current risk information.
In view of the availability of N-methylisatin-,8-thiosemicarbazone18 and vaccinia-immune gamma globulin for prophylaxis after exposure to smallpox,' and the availability in the near future of less virulent vaccinia strains, current recommendations regarding routine vaccination need to be reevaluated.
Let me stress that smallpox vaccination has been and continues to be the single most effective immunizing procedure in the eradication of smallpox in endemic reservoirs. But in view of the current small risk of the disease in this country, it has now become possible for us to assess the risk of the procedure against the risk of the disease and to suggest that routine primary vaccinations with the current virulent strain has an undue morbidity and mortality; it should be replaced as speedily as possible by less dangerous methods of providing a minimum basic antigenic experience by the use of vaccinia virus in a modified, less virulent strain. Until such strains are commercially available, routine vaccination might well be suspended and vaccinations with the current vaccine limited to groups actually at risk of exposure.
In this progress report I have tried to tell you what came of Dr. Powers' question to me 20 years ago: What price does the child pay for routine smallpox vaccination? We hope that an attenuated strain may lessen the price.
Let us recall with Osler that the great possession of any University is its great names. It is not the "pride, pomp, and circumstance" of an institution which bring honor; not its wealth, nor the number of its schools, not the students who throng its halls, but the men who have trodden in its service the thorny road through toil, even through hate, to the serene abode of fame, climbing "like stars to their appointed height." One such great name in Yale history is Grover Powers. We best honor him by loyally supporting the next generation of young teachers of pediatrics in the eternal continuum of a University.
I am grateful to you for inviting me to deliver this lecture honoring Grover Powers, and I hope that I have done him honor.
